EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Hung Wei Yang; Yu Jen Lu; Kun-Ju Lin; Sheng Chieh Hsu; Chiung Yin Huang; Shu Han She; Hao-Li Liu; Chih Wen Lin; Min Cong Xiao; Shiaw-Pyng Wey; Pin-Yuan Chen; Tzue-Chen Yen; Kuo-Chen Cheng Wei; Chen Chi M. Ma

doi:10.1016/j.biomaterials.2013.06.007

EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Hung Wei Yang, Yu Jen Lu, Kun-Ju Lin, Sheng Chieh Hsu, Chiung Yin Huang, Shu Han She, Hao-Li Liu, Chih Wen Lin, Min Cong Xiao, Shiaw-Pyng Wey, Pin-Yuan Chen, Tzue-Chen Yen, Kuo-Chen Cheng Wei, Chen Chi M. Ma^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

130 Scopus citations

Abstract

Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

Original language	English
Pages (from-to)	7204-7214
Number of pages	11
Journal	Biomaterials
Volume	34
Issue number	29
DOIs	https://doi.org/10.1016/j.biomaterials.2013.06.007
State	Published - 09 2013

Keywords

Chemotherapy
EGFR
Growth signal blocking
Nanographene oxide
Photothermal therapy
Tumor targeting

Access to Document

10.1016/j.biomaterials.2013.06.007

Cite this

@article{27d2f84cc4ff40b28438f026aa0220d0,

title = "EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy",

abstract = "Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).",

keywords = "Chemotherapy, EGFR, Growth signal blocking, Nanographene oxide, Photothermal therapy, Tumor targeting",

author = "Yang, {Hung Wei} and Lu, {Yu Jen} and Kun-Ju Lin and Hsu, {Sheng Chieh} and Huang, {Chiung Yin} and She, {Shu Han} and Hao-Li Liu and Lin, {Chih Wen} and Xiao, {Min Cong} and Shiaw-Pyng Wey and Pin-Yuan Chen and Tzue-Chen Yen and Wei, {Kuo-Chen Cheng} and Ma, {Chen Chi M.}",

year = "2013",

month = sep,

doi = "10.1016/j.biomaterials.2013.06.007",

language = "英语",

volume = "34",

pages = "7204--7214",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

number = "29",

}

TY - JOUR

T1 - EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

AU - Yang, Hung Wei

AU - Lu, Yu Jen

AU - Lin, Kun-Ju

AU - Hsu, Sheng Chieh

AU - Huang, Chiung Yin

AU - She, Shu Han

AU - Liu, Hao-Li

AU - Lin, Chih Wen

AU - Xiao, Min Cong

AU - Wey, Shiaw-Pyng

AU - Chen, Pin-Yuan

AU - Yen, Tzue-Chen

AU - Wei, Kuo-Chen Cheng

AU - Ma, Chen Chi M.

PY - 2013/9

Y1 - 2013/9

N2 - Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

AB - Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

KW - Chemotherapy

KW - EGFR

KW - Growth signal blocking

KW - Nanographene oxide

KW - Photothermal therapy

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84879605060&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.06.007

DO - 10.1016/j.biomaterials.2013.06.007

M3 - 文章

C2 - 23800742

AN - SCOPUS:84879605060

SN - 0142-9612

VL - 34

SP - 7204

EP - 7214

JO - Biomaterials

JF - Biomaterials

IS - 29

ER -

EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this